Metagenomi inc MGX.US Overview Analysis
MGX AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
MGX Current Performance
9.66%
Metagenomi inc
1.31%
Avg of Sector
0.58%
S&P500
Top 10 High Relevance to MGX
- QURE Uniqure nvValue 2Trend 3Swing Trading 4Whale Interest 3Dividend 1See more
MGX Profile
Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.